Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma

doi:10.3389/fpubh.2022.963058

HFCAS OpenIR

	Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma
	Shao, Guoliang 1,2; Wang, Jingwen 3; Zhou, Xiaoying 3; Sun, Guojun 3; Dong, Zuojun 3
	2022-10-26
发表期刊	FRONTIERS IN PUBLIC HEALTH
通讯作者	Dong, Zuojun(jzd1970@zjut.edu.cn)
摘要	ObjectiveTo conduct a cost-effectiveness analysis of drug-eluting beads transcatheter arterial chemoembolization (DEB-TACE) and conventional transcatheter arterial chemoembolization (cTACE) for first-line treatment of hepatocellular carcinoma (HCC) from the perspective of the Chinese healthcare system. MethodsBased on the real-world clinical data of HCC patients receiving interventional therapy, a partitioned survival model was constructed for cost-effectiveness analysis. The model period is 1 month, and the research time limit is 10 years. The incremental cost-effectiveness ratio (ICER) is used as the evaluation index. One-way sensitivity analysis and probabilistic sensitivity analysis were used to analyze the uncertainty of parameters to test the stability of the model results. ResultsThe ICER of the DEB-TACE group was 11,875.62 $/QALYs, which was lower than the willingness to pay threshold (WTP) of 31,499.23 $/QALYs. One-way sensitivity analysis suggested that the utility value of progression-free survival (PFS) in the DEB-TACE group had the greatest impact. Probabilistic sensitivity analysis showed that at the level of WTP of 31,499.23 $/QALYs, DEB-TACE had a cost-effective probability of 92%. ConclusionUnder the current economic level in my country, DEB-TACE is more cost-effective than cTACE in the treatment of HCC patients.
关键词	DEB-TACE cTACE partition survival model cost-effectiveness analysis hepatocellular carcinoma
DOI	10.3389/fpubh.2022.963058
关键词[WOS]	CANCER STATISTICS ; SURVIVAL ; CHINA
收录类别	SCI
语种	英语
资助项目	National Natural Science Foundation of China ; [82072032]
项目资助者	National Natural Science Foundation of China
WOS研究方向	Public, Environmental & Occupational Health
WOS类目	Public, Environmental & Occupational Health
WOS记录号	WOS:000882370600001
出版者	FRONTIERS MEDIA SA
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/130426
专题	中国科学院合肥物质科学研究院
通讯作者	Dong, Zuojun
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Intervent Therapy, Canc Hosp, Hangzhou, Peoples R China 2.Zhejiang Univ, Precis Innovat Ctr Diag & Treatment Hepatobiliary, Hangzhou, Peoples R China 3.Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Shao, Guoliang,Wang, Jingwen,Zhou, Xiaoying,et al. Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma[J]. FRONTIERS IN PUBLIC HEALTH,2022,10.
APA	Shao, Guoliang,Wang, Jingwen,Zhou, Xiaoying,Sun, Guojun,&Dong, Zuojun.(2022).Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma.FRONTIERS IN PUBLIC HEALTH,10.
MLA	Shao, Guoliang,et al."Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma".FRONTIERS IN PUBLIC HEALTH 10(2022).